Endovascular treatment for wide-necked intracranial aneurysms with the Enterprise stent.
The development of self-expanding stents dedicated to intracranial use has significantly widened the applicability of endovascular therapy to many intracranial aneurysms To report the angiographic and clinical outcomes of wide-necked intracranial aneurysms treated using the Enterprise stent. Forty-six patients with 50 wide-necked and fusiform aneurysms (19 aneurysms with dissections), admitted between June 2009 and December 2010, were treated using Enterprise stents. Demographic information, procedural data, and technical complication were reviewed. Angiographic and clinical outcomes were evaluated at a 9.1-month follow-up. Stent deployment was successful in all the 50 lesions, and additional coil embolization was performed in 48. Complete or near-complete occlusion immediately after stent deployment was achieved in 44 aneurysms, whereas, no immediate coil embolization was chosen in two cases. There was one (2%) procedure-related complication, which resulted in death. At mean 9.1-month follow-up, the result was good (GOS ≤2) in 45 patients. Angiographic recurrences arose in two cases, one of which was re-treated completely. The Enterprise stent is very useful for endovascular embolization of wide-necked intracranial aneurysms, because it is easy to navigate and place precisely. The overall morbidity and mortality rates are low.